Skip to main content

Rubin Paul D's Form 4 filing

BioAge Labs, Inc. (BIOA) · filed Apr 3, 2026

Accession no.
0001210905-26-000011
Filed
Apr 3, 2026
Trade date
Apr 1, 2026
Filing delay
2 days
Rule 10b5-1 plan
Checked

This filing lists 3 non-derivative transactions and 2 derivative transactions. Open-market sales total $157.1K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Rubin Paul DCIK 0001210905Officer (Chief Medical Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Apr 1, 2026Common StockMOption exerciseAcquired+5,437$4.11+$22,346.075,437Direct
Apr 1, 2026Common StockMOption exerciseAcquired+3,383$6.57+$22,226.318,820Direct
Apr 1, 2026Common StockSSaleDisposed−8,820$17.81−$157,084.20Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Apr 1, 2026Common StockMOption exerciseDisposed−5,437$0.00$00Direct
Apr 1, 2026Common StockMOption exerciseDisposed−3,383$0.00$00Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

No transaction price on this filing refers to a footnote.

Read the full filing on SEC EDGAR (opens in a new tab)